Crystal Pharmatech Holdings: Achieved Profitability in 2025 with Annual Profit of 135 Million Yuan, Multiple Collaborations Totaling Hundreds of Billions of Yuan

Jingtai Holdings announced its 2025 performance report recently, stating that the company achieved operating revenue of 803 million yuan, a year-on-year increase of 201.2%. The annual profit was 135 million yuan, turning around from a loss of 1.515 billion yuan in the same period of 2024. The adjusted net profit was 258 million yuan, significantly better than the loss of 457 million yuan in 2024.

The announcement mentioned that in 2025, the group’s business achieved a series of important results:

1. Empowered and incubated 5+ global first-in-class/best-in-class innovative pipelines entering clinical or IND-enabling stages, covering fields such as oncology, autoimmune diseases, neurodegenerative diseases, and chronic illnesses;

2. Several major collaborations were established, with a total cooperation amount reaching hundreds of billions of RMB, maintaining a leading position in AI application industry;

3. The number of revenue-generating customers in 2025 increased by 62% year-on-year. To date, the company has covered 17 of the top 20 global pharmaceutical companies, successfully delivering across multiple scenarios and gaining recognition from top international clients;

4. The group has developed over 200 industry AI models, and in 2025, successfully expanded new drug innovation platforms including molecular gels, peptides, and small nucleic acids, further strengthening full-stack capabilities;

5. Intelligent agents independently advance over ten thousand compound experiments weekly, completing the R&D closed-loop;

6. Successfully expanded into new fields such as new materials and consumer health.

(Jingtai Holdings Announcement)

(Editors: Yang Yan, Lin Chen)

Keywords: Medical